3K3A-Activated Protein C

3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech. It is also being assessed for the treatment of Alzheimer's disease. It is the subject of RHAPSODY, a phase II trial to determine safety and tolerability.

A phase III trial, RHAPSODY-2, to determine safety and efficacy for treatment of ischemic stroke, is planned. However, on November 16, 2023, the National Institutes of Health (NIH) paused the start of the human trial of 3K3A-APC after an investigation by Science Magazine.

The drug was designed to have more activity at protease-activated receptor 1 (PAR-1) and less anticoagulative effect than activated protein C.